
|Articles|June 10, 2020
ERT Acquires APDM Wearable Technologies
Advertisement
ERT has announced the acquisition of APDM Wearable Technologies, a provider of wearables and digital biomarkers. By integrating Patient Reported Outcomes data captured by ERT’s eCOA platform with data from APDM’s wearables and digital endpoints, trial sponsors gain insights as they develop new medical treatments for many therapies, including movement-related disorders. The integrated solution can be used to support in-clinic assessments as well as in trials conducted virtually.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
2
From Participation to Understanding: Reframing Engagement in Clinical Trials
3
Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable
4
ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD
5




